Paper Details

  1. Home
  2. Paper Details

An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.

Author: BagshawHilary P, BerlinAlejandro, ChenRonald, DessRobert T, FengFelix Y, GarciaJorge A, GuoGordon, JacksonWilliam C, KishanAmar U, KoontzBridget, MorgansAlicia K, NagarHimanshu, NguyenPaul, PonskyLee, PosadasEdwin, RoySoumyajit, ShoagJonathan E, ShoreNeal D, ShowalterTimothy N, SolankiAbhishek, SprattDaniel E, StishBradley, TranPhuoc T, TreeAlison, TurnerSandra, ZaorskyNicholas G

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Relugolix, the first oral GnRH antagonist, offers faster and more complete testosterone suppression compared to LHRH agonists for prostate cancer treatment. The drug's rapid onset and offset of testosterone suppression allows for more precisely defined treatment duration, particularly when combined with radiation therapy.
Paper Details　
Original Abstract of the Article :
Androgen deprivation therapy (ADT) is an integral component in the management of prostate cancer across multiple disease states. Traditionally, luteinizing hormone-releasing hormone (LHRH) agonists constituted the backbone of ADT. However, gonadotropin-releasing hormone receptor hormone (GnRH) antag...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijrobp.2021.12.005

データ提供：米国国立医学図書館（NLM）

Relugolix and Radiation Therapy: Navigating the Prostate Cancer Desert

Prostate cancer, a complex and challenging disease, often requires a multi-pronged approach to treatment. This expert review explores the potential of combining relugolix, a novel oral GnRH antagonist, with definitive radiation therapy for prostate cancer. The researchers delve into the advantages and considerations of this combination therapy, aiming to provide guidance for clinicians managing this disease.

Finding a Synergistic Oasis in the Prostate Cancer Desert

The researchers, like skilled desert guides, carefully analyze the benefits of combining relugolix with radiation therapy. Relugolix offers faster and more complete testosterone suppression compared to other therapies, potentially enhancing the effectiveness of radiation therapy. The oral formulation of relugolix provides greater convenience for patients, making treatment more manageable.

A Path to Personalized Care in the Prostate Cancer Desert

This expert review emphasizes the need for a personalized approach to prostate cancer treatment. By considering the specific needs of each patient, clinicians can choose the most effective combination therapy, ensuring optimal outcomes and minimizing potential side effects. This research provides valuable insights into the potential benefits of combining relugolix with radiation therapy, offering a path to more personalized and effective care.

Dr.Camel's Conclusion

This expert review sheds light on the potential benefits of combining relugolix with radiation therapy for prostate cancer. By offering a more personalized and effective approach, this combination therapy may provide a new oasis in the desert of prostate cancer treatment, improving outcomes and enhancing quality of life for patients.

Date :
  1. Date Completed 2022-05-17
  2. Date Revised 2022-07-15
Further Info :

Pubmed ID

34923058

DOI: Digital Object Identifier

10.1016/j.ijrobp.2021.12.005

Related Literature

Article Analysis
・Side Effects of relugolix
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.